



TSXV:KHRN | OTCQX:KHRNF
FRANKFURT:A2JMZC



IMPROVING LIVES GLOBALLY
THROUGH MEDICAL CANNABIS

MARCH 2022



We create
the way
together...
**AS
ONE**

LEGAL NOTICES

This information in this presentation is current as of September 30, 2021 unless otherwise indicated. The information contained in this presentation is provided for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Khiron. No part of this presentation shall form the basis or be relied upon in connection with any contract, commitment or investment decisions in relation thereto. The information contained herein is not investment advice and is not intended to be used as the basis for making an investment decision. No securities commission or similar regulatory authority in Canada has reviewed this presentation. Investors and prospective investors should rely only on the information contained in the continuous disclosure filings of Khiron on www.SEDAR.com under Khiron's issuer profile. This presentation is qualified in its entirety by reference to, and must be read in conjunction with, such filings.

This presentation contains "forward-looking statements," within the meaning of applicable Canadian securities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, assumptions and analyses made by us regarding the future of our business, future plans and strategies, our operational results and other future conditions. These forward-looking statements appear in a number of places throughout this presentation and can be identified by the use of words, such as "anticipates," or "believes," "budget," "estimates," "expects," or "is expected," "forecasts," "intends," "plans," "scheduled," or variations of such words and phrases or state that certain actions, events or results "may," "might," "will," "would," "could," "should," "continue," or be taken, occur or be achieved. These forward-looking statements relate to, among other things, our future financial performance, financial condition, liquidity, levels of activity, performance, prospects, growth, goals or achievements or other future events. Although we base the forward-looking statements contained in this presentation on assumptions that we believe are reasonable, these forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual performance and financial results in future periods to differ materially from those anticipated in our forward-looking statements, including those risk factors identified in Khiron's most recent MD&A, AIF and other disclosure documents available on SEDAR at www.SEDAR.com under Khiron's issuer profile. Forward-looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made have on our business. For example, they do not include the effect of asset impairments or other charges announced or occurring after the forward-looking statements are made. The financial impact of such transactions and non-recurring and other special items can be complex and necessarily depends on the facts particular to each of them. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. The purpose of the forward-looking statements is to provide the reader with a description of management's expectations regarding our anticipated future performance and may not be appropriate for other purposes. Furthermore, unless otherwise stated, the forward-looking statements contained in this report are made as of the date of this report and we do not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise unless required by applicable legislation or regulation. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

Market Research and Public Data: This corporate presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although we believe these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. We have not independently verified any of the data from third party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed.

Future Oriented Financial Information: To the extent any forward-looking information in this corporate presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above. Our actual financial position and results of operations may differ materially from management's current expectations and, as a result, our revenue and profitability may differ materially from the revenue and profitability profiles provided in this corporate presentation. Such information is presented for illustrative purposes only and may not be an indication of our actual financial position or results of operations.

Use of Non-GAAP Measures: This document refers to certain financial performance measures that are not defined by and do not have any standardized meaning under GAAP and are used by management to assess the financial and operational performance of the Company, including EBITDA, because certain investors may use this information to assess our performance and also determine our ability to generate cash flow. This data is furnished to provide additional information and are non-GAAP measures and do not have any standardized meaning prescribed by GAAP. They should not be considered in isolation as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of operating costs presented under GAAP.

KHIRON: Growing company in a global growing industry

Founded in 2017, Khiron aims to improve the quality of life of patients in Latin America and Europe, becoming the leading medical cannabis brand in these regions

1,200%

Medical Cannabis
Sales Growth YoY
2021

Offering products &
services our patients
need

>85%

Gross Profitability on
Medical Cannabis
Products

Focus on adding value
& building brands for
sustainable growth

5

Countries with sales in
Europe & LatAm

Diversified patient
base and 1st global
medical cannabis clinic
network

Exponential and sustainable growth


Khiron focuses on improving the quality of life of patients through the applied use of medical cannabis.

Our unique B2C strategy makes Khiron one of the **fastest** growing companies in LatAm and Europe

Khiron LatAm

Colombia, Peru, Brazil


Sales Volume
Oil-based units



Khiron Europe

UK, Germany

Sell-Out Volume
Cannabis Flower in grams



Adding Value for Sustainable Profitability

Khiron's strategy is focused on ensuring access to safe services and medical cannabis products, creating value for our patients

Latin America

Vertically integrated, producing pharmaceutical-grade medication from low-cost Colombian facility

Europe

Efficient, agile EU-GMP supply network with exclusive and own genetics





>85%

Gross Profitability on
Medical Cannabis
Products



Established Presence in International Markets

Medical cannabis is the largest disruptor to the opioid pharmaceutical market in LatAm and Europe




(1) Prohibition Partners - The Latin America and Caribbean Cannabis Report 2nd Edition
 (2) Prohibition Partners - The European Cannabis Report Edition 6th and management estimates
 (3) Management estimates

A top selling brand in LatAm and Europe

- Khiron began sales of medical cannabis in March 2020 in Colombia
- Today the Company sells in 5 countries in Latin America and Europe, looking to begin sales in Mexico in 2022

EUROPE 2021


Almost 100,000 grams dried-flower sold



■ Germany ■ UK

LATIN AMERICA 2021

> 54,000 units sold



■ Colombia ■ Peru

KHIRON IN LATAM

- Leveraging 1st mover advantage to become the top selling medical cannabis brand in the region
- Vertical integration with own health centers and clinics focused on ensuring and providing access to patients, we cover full value chain from seed to patient

>20,000

Medical cannabis patients in LatAm

Colombia, Peru, Brazil,
(Mexico 2022)

16

Medical cannabis clinics worldwide

Colombia, Peru, UK, Brazil (Q2 2022), Mexico (Q2 2022)


>50%

Patient retention in medical cannabis

60%

insurance coverage

Patients covered by insurance in Colombia in 2021



»»» **Bogota,
Colombia**

KHIRON IN EUROPE

Quickly earning market share in less than 1 year of operations

- **Currently the top medical cannabis brand in the UK market**
- **Currently top selling CBD-predominant Cannabis flower in Germany**
- Lead by **Franziska Katterbach**, President Khiron Europe, former Director of Legal for Canopy's European Operations with more than **5 years'** experience in the cannabis industry in Europe
- One of the fastest growing medical cannabis companies in the region, operating in UK and Germany
- Represented about **30%** of Khiron's total cannabis sales in 2021 with more than **90%** gross margins
- More than **30** team members in Germany, UK and Spain
- Opened its first European medical cannabis clinic (www.zereniaclinic.co.uk) in November 2021

22x
Growth in sell-
out in 1 year

>90%
Gross Margin

»» HOW?

TEAM
STRATEGY
PRODUCT
AGILITY
HIGH MARGIN

Local & experienced
Education through RWE
Demand for our products
Asset-light, patient focused
Focus on value to patient
and prescribers

Khiron: Differentiated Strategy, Unique Pillars

**Cannabis is a
Treatment
Option for
Patients**

**Real World
Evidence
Turned Into
Education**

**Offer Products
That Patients
Actually Need**

**Execution
Before
Expansion**

**Experienced
Regional
Teams**

**Flexible and
Scalable
Operations**

**Short-term
Path To
Profitability**


**Focused on
Demand
Generation**

GROWTH TRAJECTORY


Patient-focused strategy improving profit margins consistently

Values in Million CAD


Consistent Overall Revenue Growth QoQ




Cannabis Driving Sales Growth



Consecutive Growing Sales in Europe and LatAm




Cannabis Driving Gross Profitability



Capital Structure

B2C, patient-focused strategy improving profit margins significantly and consistently
Values in Million CAD

Gross Profitability Reducing EBITDA losses



	FD (millions)	Strike price range (C\$)	W. Avg (C\$)
Basic Common S/O	179		
Warrants	62	\$0.45 - \$0.9	\$0.8
Options	4.6	\$0.75 - \$3.25	\$1,7
RSUs	7.8	n/a	n/a
Total (fully diluted)	253		

(C\$Ms)	30-Sept-21
Cash	15.1
Current assets (excl. cash)	16.7
Non-current assets	34.2
Total Assets	66
Current liabilities	6.1
Non-current liabilities	4.9
Shareholders equity	55
Total Liabilities and SH Equity	66

Capital Structure ¹	
Basic shares outstanding	179 million
FD S/O	253 million
Recent share price (CAD)	\$0.25
Market Cap(CAD, basic)	\$45 million

¹ As of November 19, 2021

Investment Opportunity

Trading at discount despite higher revenues, margins, and pricing

Large, rising addressable market

- 1 billion + people in LatAm and Europe
- Over 6 million potential patients by 2025

Fast-growing, highly profitable medical cannabis revenues

- 1,200% revenue growth
- 85% gross profits

Unique, differentiated strategy


- 1st mover advantage in LatAm & Europe
- Generating unique real-world evidence

Path to profitability within striking distance

- >85% gross profits
- Double digit profitability growth within next 2 years

Trading at Discount within the Industry


EV / Twelve Trailing Months Revenues



1) IMCC, PCLO, AVCN, FLGC, RAMM, CLVR, INCR, LGP, CPH

2) <https://www.valuationresearch.com/wp-content/uploads/2022/02/Cannabis.pdf>

Investment Highlights





KHIRON
L I F E S C I E N C E S C O R P

VISIT KHIRON ONLINE AT
INVESTORS.KHIRON.CA

INVESTORS@KHIRON.CA

T: +1 (647) 556 5750

ALVARO TORRES

Co-founder & CEO

Bogotá, Colombia

Email: aftorres@khiron.ca

FRANZISKA KATTERBACH

Europe President

Frankfurt, Germany


Email: fkatterbach@khiron.ca



TSXV:KHRN | OTCQX:KHRNF | FRANKFURT:A2JMZC



ANNEX



TSXV:KHRN | OTCQX:KHRNF | FRANKFURT:A2JMZC

We create
the way
together...
**AS
ONE**

A Diverse, Experienced Management Team



Alvaro Torres

CEO

- Industrial Engineer (RPI), MBA (Georgetown University)
- 15+ years experience in top management of infrastructure sector in LatAm. Formerly with SNC-Lavalin building company's presence in Colombia. Has overseen more than US\$ 1 Billion infrastructure projects in development and completion



Franziska Katterbach

- 8+ years of regulatory expertise and 5+ as business executive in the European emerging cannabis industry
- Pioneer of the medical cannabis market in Germany, working in the medical cannabis industry in Europe on executive level since the very beginning in 2016
- Previously working for Dentons involved in high profile cannabis deals across multiple jurisdictions. Later served as Director for Canopy's European operations



Swapan Kakumanu

CFO

- 25+ years of senior finance and operations experience both in public and private companies
- Prior experience senior roles as President, Chief Executive Officer, Chief Financial Officer, Controller, Company Secretary, and Board Member for public and private companies



Rodrigo Duran

VP KhironMed

- 17+ years of experience in CPG & Pharma marketing, sales and go-to-market strategies, managing teams, and bringing brands across the Latam markets
- Former manager executive of Team Food, Pfizer and Wyeth



Juan Diego Alvarez

VP Regulatory Affairs

- Ph.D., Law and public health, Tulane University
- 10+ years of experience of legal experience in Colombian & Latam medical cannabis regulation. Appointed by Minister of Health to create and draft regulations for legalization of medical cannabis

Experienced Independent Board Of Directors



Chris Naprawa

Chairman of the Board

- 20+ years of experience in institutional capital markets.
- Former partner at Sprott Capital Partners, Head of Equity Sales at Macquarie Canada, Head of Equity Sales and Trading at Dundee Securities and Managing Director at Primary Capital.



Alvarez Torres

Co-founder & Director

- Industrial Engineer who built infrastructure projects in Colombia and LatAm.
- Formerly with SNC Lavalin and successfully built an engineering and merchant banking firm.



Deborah Rosati

Lead Director

- Over 30 years of experience, including in consumer, cannabis, private equity and venture capital.
- Vice Chair & Chair of the Audit Committee at cannabis authority.
- Founder & CEO of Women Get on Board, Former Chair of the Audit Committee at Sears Canada Inc., member of the Department Audit Committee at Correction Services Canada, and former Board member and Chair of the Audit Committee. at NexJ Systems Inc.



Juan Carlos Echeverry

Independent Director

- Served as Colombia's Minister of Economic Planning in 2000 and was the representative for Colombia before the Inter-American Development Bank (IDB).
- Former CEO and President of Ecopetrol, Colombia's largest corporation and the 4th largest Latin American oil and gas producer included in Fortune Global 500.



Alvaro Yañez

Independent Director

- 15 years of legal experience in Colombia and internationally.
- Former Legal Manager of Frontera Energy (formerly known as "Pacific Exploration and Production").



Vincente Fox

Independent Director

- Mexican businessman and politician who served as 55th President of Mexico.
- Former CEO Coca-Cola Mexico.

World-class Operations in LatAm



Cultivation & Extraction

Fully licensed for commercial THC and CBD cultivation, extraction & sales in Colombia

- Total area of 20 Ha. Current cultivation area of **80,000 sq.ft.**
- Obtained **17%** of Colombia's total allocation of THC quotas for 2020. 1st company to do so in Colombia

State-of-the-art, **14,000 sq.ft.** GMP-compliant post-harvest facility in Doima, Colombia (157 Km west of Bogota)

Production Capacity

- Cultivation: Upwards of **9 tonnes**¹ of dried flower
- Extraction: Up to **3 tonnes** of full-spectrum extract², with capacity to expand within building
- ~1 MW Solar Park resulting in up to 40% energy cost reduction

1 – Mgmt estimations @ stability of crops, 2 – Based on management estimates, 3 – Define as infrastructure & equipment max production capacity




Zerenia Medical Services

Integrated care providing one stop shop to meet broad patient needs, build loyalty



WITH
MEDICAL
CANNABIS



Chronic Pain

Palliative Care

Neurology

Mental Health

Sleep Disorders

Physiotherapy

March

Laboratory


Hydrotherapy

General Consults

Neurosurgery

Minor

Procedures



Khiron First Sustainability Report 2020

Thinking in ESG since inception



ALIGNED TO INTERNATIONAL
BEST PRACTICES



Sustainability Matters

Thinking in ESG since inception

